Cytokinetics could make more geography-centric deals as regulators in the United States, Europe and China review the company's potential blockbuster drug for approval. Cytokinetics Inc.
Kelun-Biotech has become the second drugmaker to bring a TROP2-directed antibody-drug conjugate to regulatory approval, getting a green light in China for sacituzumab tirumotecan (sac-TMT).
As we near the end of our “emerging markets” focus month, Chia Wen Lee and Betty Su share their thoughts on the status of orphan drugs in China, one of the largest emerging markets in the world.
Talkie, the popular personalised artificial intelligence (AI) app developed by Chinese start-up MiniMax, has been removed from Apple’s US App Store due to unspecified “technical reasons”.